AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections

Introduction

The risk of opportunistic infections (OIs) in inflammatory bowel disease increases with the use of biologics compared with placebo (odds ratio [OR]: 1.90).¹ Vedolizumab (VDZ), a humanised monoclonal antibody, targets α₄β₇ integrin and selectively blocks gut-specific lymphocyte trafficking. Gut selectivity may be associated with a lower risk of infection compared with anti-tumour necrosis...